Relmada Therapeutics (RLMD) Misses Q3 EPS by 84c

Relmada Therapeutics (NASDAQ: RLMD) reported Q3 EPS of ($2.44), $0.84 worse than the analyst estimate of ($1.60).

As of September 30, 2021, the Company had cash and short-term investments of $88.1 million, compared to cash, cash equivalents, and short-term investments of approximately $117.1 million at December 31, 2021.

For earnings history and earnings-related data on Relmada Therapeutics (RLMD) click here.

You May Also Be Interested In

• Royal Caribbean to acquire 50% stake in Sandals Resorts for $3 billion
• Oppenheimer Starts Teva Pharma (TEVA) at Outperform
• Goldman Sachs Downgrades Bank Mandiri (BMRI:IJ) (PPERF) to Sell, 'Liquidity and capital tightness'